Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In this single-dose, randomized, 5-way cross-over study, healthy volunteers were treated with
the highest approved dose of octreotide, three different doses of Somatoprim (DG3173) and
placebo control. The main purpose of the study was to investigate the effects of each
treatment on the control of plasma glucose as well as the secretion of insulin and glucagon
following a standard meal.